Whalesbook
Mixed Performance: Domestic Sales vs. US Generics
The Indian pharmaceutical sector reported a mixed Q4 FY26, with strong domestic market growth largely compensating for a sharp drop in US generics sales. Analysts forecast sector revenue to grow by about 12%, but expect net profit to fall by 14% year-on-year due to these market dynamics.
Revlimid Loss Hits US Generics Sales
The loss of US patent exclusivity for the drug Revlimid remains a major factor impacting earnings for key Indian pharmaceutical companies. Dr. Reddy's Laboratories, Cipla, and Zydus Lifesciences, which relied heavily on this drug, are expected to report significant profit declines. Systematix anticipates US revenue drops of 22% for Cipla and 37% for Dr. Reddy's, pushing their US business back towards pre-Revlimid profitability levels. Cipla also faced issues like supply disruptions for its drug Lanreotide.
Domestic Market Strength
India's domestic formulations market is proving to be a key support for the sector. Most large Indian drugmakers are projected to achieve double-digit growth at home. This is driven by stable demand for chronic therapies, steady acute treatments, and new product launches. Companies like Sun Pharma, Cipla, Dr. Reddy's, Mankind Pharma, and Ajanta Pharma are expected to see low-to-mid teen growth in domestic revenues. Chronic therapies are increasingly important, signaling a shift in India's healthcare consumption.
Rising Costs Squeeze Margins
Tensions in the Middle East have increased costs for freight and raw materials, even though demand for medicines remains stable. Higher shipping routes and surcharges are impacting profitability, partially offsetting gains from a weaker rupee. Analysts warn that persistent geopolitical issues could further inflate these costs, directly affecting exporters. These increased expenses contribute significantly to margin compression across the sector.
Resilient Companies Show Growth Strategies
Despite sector-wide challenges, companies like Lupin and Ajanta Pharma are showing strong performance. Lupin's earnings are boosted by continued exclusivity for its drug Tolvaptan and successful niche product launches. Ajanta Pharma's US business is also growing, supported by its specialized product offerings. These companies demonstrate how strategic market advantages and product differentiation can help navigate a tough US generics market.
Valuations and Currency Effects
Valuation multiples vary across companies. Sun Pharma trades at a higher valuation (around 36.7 times earnings) compared to Dr. Reddy's (18.4) and Zydus Lifesciences (18.9). Cipla is around 21.7, Lupin at 22.8, and Ajanta Pharma at 34.4. A weaker rupee (now over 90 against the dollar) theoretically boosts revenue for exporters in rupee terms. However, this is partly cancelled out by rising costs for imported raw materials, often from China.
Key Risks Ahead
Significant risks persist despite domestic growth. Reliance on a few major products, as seen with Revlimid, leaves companies vulnerable. Continued price drops in the US generics market remain a major threat. Geopolitical tensions in the Middle East pose ongoing risks to supply chains and costs. Operational issues, such as recalls or production disruptions for companies like Cipla, can worsen margin pressures and affect investor confidence. Increased investment in R&D and specialty products, while vital for future growth, creates near-term margin pressure.
Outlook: Navigating Future Challenges
Looking ahead, the sector's performance will depend on its ability to manage the ongoing US market changes while capturing domestic growth. Analysts expect moderate overall revenue growth, but profit margins will likely stay under pressure due to higher costs and competition. Companies focused on diversifying their product portfolios, investing in high-margin specialty products, and maintaining cost discipline are best positioned for sustainable growth.